

Cancer Test Requisition Form (Abbreviated)

COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES TO AVOID DELAYS

To submit an order via email, please send the completed test requisition form to info@ambrygen.com

Date:

1. SPECIMEN INFORMATION (Please see

Collection Date

(Required) If date of collection is not provided, three calendar days before				PLEASE SUBMIT THE FOLLOWING WITH THE TRF:								
specimen receipt will be used (for specimens stored longer than 30 days, the day of archive retrieval will be used as the date of service)				1.	Clinic Notes	2. Pedigree	Pedigree 3. Insurance Card and Authorization Documen					
2. PATIENT INFORMAT	ION											
Legal Name (Last, First, MI)							Date of Birth (MM/E	Sex Assigner at Birth		☐ Man ☐ Woman ☐ Nonbinary		
Genetic Ancestry: ☐ Ashkena: ☐ Middle Eastern ☐ Native A								□Med	literranean		MRN	
Address					City					State Zip		
Mobile #				Email					Preferred Billing ☐ Insurance ☐ Self-pay ☐ Institutional			
3. ORDERING PROVIDE	R INF	ORM <i>A</i>	NOITA									
Organization Name, Number				Address City, State			ate	Zip				
Ordering Provider Name (Last, First), Ambry Number , NPI												
Genetic Counselor/Other Healthcare Professional Name (Last, □				t, First), Ambry Number								
4. PERSONAL AND FAN	AILY H	IISTO	RY OF CANC	ER Attach cli	nic notes and/	or pedigree						
Personal History of Cancer: 🗆 `	Yes □ N	No A	ge of Dx:		Metastati	ic: ☐ Yes ☐ No Tumor is ☐ MSI-High or ☐ IHC-Abn				ormal ICD-10 Code(s)		
Testing could aid in systemic th	nerapy a	nd/or s	surgical decision	-making for my	affected patier	nt □ Yes □ No	Abnormal IHC Res	sult:				
Patient Cancer Type Details:							,					□TNBC
Family History of Cancer: ☐ Ye	s 🗌 No		Known Familia	l Variant: ☐ Fan	nily Self (Gene: Variant (c. and/or p.): Ambry ID:						
Relationship to Patient Mat Pat Age at Dx			Age at Dx	Family Testing and Cancer Type Details					Reason relative has not been tested			
										□Dece	ased 🗆 Decline	s 🗌 No Contact
									☐ Deceased ☐ Declines ☐ No Contact			
									□ Deceased □ Declines □ No Conta			
						ased Decline	s No Contact					
										Dece	ased 🗌 Decline	s 🗆 No Contact
5. TEST ORDERS												
REQUIRED: Select a Primary Test Order				Select an Optional Supplemental Test (Per payer policy, all tests in this section will be processed and billed separately; tests may be performed as a reflex.)								
For Patients Meeting BRCA1/2 Testing Criteria					☐ CancerNext® (8824) ☐ CancerNext®				-Expanded® (8875)			
□ BRCA1/2 test					☐ BRCANext® (8857) ☐ CustomN				Limited Evidence Pancreatitis			
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (Lynch)				CustomNext-Cancer® (9511) Notes:								
Lynch Syndrome test: MLH1, MSH2, MSH6, PMS2, EPCAM				ColoNext® (8821)			☐ Specific Site Analysis (5555): Proband report is requi			eport is required.		
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (polyposis) Polyposis test: APC/MUTYH								Variant (c./p.):				
<u> </u>					Other Supplemental Test Options (Select if applicable)							
□ Other: □ None of the above (patient does not meet any genetic testing criteria)					□+RNAinsight® (Not available with BRCAplus or STAT orders; PAXgene® tube required for RNA)							
Collection Assistance: Phle								,	,	, . ,	<u> </u>	,
STAT TEST: 🗌 Date results needed (if known):												
Patient Signature (I agree to terms below): Date:												

TERMS AND CONDITIONS

Medical Professional Signature (I agree to terms below):

Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company.

In agree to be contacted regarding future research studies for which I may be a candidate. Any future research projects will be subject to a separate informed consent process and participation is voluntary. Learn more about Ambry's privacy practices at https://www.ambrygen.com/legal/notice-of-privacy-practices.

For patient payment by credit card: I hereby authorize Ambry Genetics Corporation to bill my credit card as indicated above. In order to expedite consideration for eligibility for Ambry's Patient Assistance Program, please provide the total annual gross household income: \$ and the number of family members in the household supported by the listed income: . I authorize Ambry Genetics Corporation to verify the above information for the sole purpose of assessing financial need, including the right to seek supporting documentation

For NY Residents: By checking this box, I agree that Ambry Genetics will retain my sample for 6 months after the testing above has been completed. By not checking this box, I understand that under New York State law, Ambry Genetics must discard my sample after the longer of (a) testing completion and (b) 60 days after the Date of Collection above.

Medical Professional: Confirmation of Informed Consent, Pre-test Genetic Counseling, and Medical Necessity for Genetic Testing

The undersigned person (or representative thereof) ensures he/she is a licensed medical professional authorized to order genetic testing and confirms that the patient has given appropriate consent.

I confirm that testing is medically necessary and that test results may impact medical management for the patient. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider. Furthermore, all information on this TRF is true to the best of my knowledge. My signature applies to the attached letter of medical necessity.



Supplemental Information

Hereditary Cancer Multi-Gene Tests

TEST NAME	TEST CODE	GENES			
Pan-cancer					
CancerNext® (40 genes)	8824	APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, GREN HOXB13, MBD4, MET, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RADS RAD51D, RPS20, SMAD4, STK11, TP53, TSC1, TSC2, VHL			
CancerNext-Expanded® (77 genes or up to 90 genes w/ add-ons)	8875	AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, EGFR, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1			
		Optional Add-on 1 - Limited Evidence Genes (8 genes): ATRIP, EGLN1, KIF1B, MLH3, PALLD, RAD51B, RNF43, TERT			
		Optional Add-on 2 - Pancreatitis Genes (5 genes): CFTR, CPA1, CTRC, PRSS1, SPINK1			
STAT Breast Management					
BRCAPlus® (13 genes)	8836	ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53			
Breast & gynecologic	'				
BRCANext® (19 genes or up to 26	8857	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53			
genes w/ add-on)		Optional Add-on - Limited Evidence Genes (7 genes): ATRIP, CDC73, FH, NTHL1, POLD1, POLE, RAD51B			
Colorectal & polyposis	,				
ColoNext® (21 genes or up to 26 genes w/ add-on)	8821	APC, AXIN2, BMPR1A, CDH1, EPCAM, GREM1, MBD4, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RPS20, SMAD4, STK11, TP53			
genes w/ add-on/		Optional Add-on - Limited Evidence Genes (5 genes): ATM, CHEK2, CTNNA1, MLH3, RNF43			
Customizable					
	9511	To order all genes on Ambry's oncology menu, please order CancerNext-Expanded.			
CustomNext-Cancer® (up to 90 genes) Required: complete CustomNext-Cancer supplemental form. ambrygen.com/forms		AIP, ALK, APC, ATM, ATRIP, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CFTR, CHEK2, CPA1, CTNNA1, CTRC, DICER1, DDX41, EGFR, ELGN1, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PALLD, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RET, RNF43, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WT1			
		For Medicare Patients: At a minimum, the following core genes must be included in the panel to ensure Medicare coverage: APC, ATM, BRCA1, BRCA2, CHEK2, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, TP53.			
Syndrome specific					
Adenomatous polyposis	8726	APC, MUTYH			
BRCA1/2-associated hereditary breast and ovarian cancer (HBOC)	8838	BRCA1, BRCA2			
Lynch syndrome	8517	MLH1, MSH2, MSH6, PMS2 + EPCAM del/dup			



Patient Name:	DOB:	

Supplemental Information

Specimen Requirements

Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. Please see ambrygen.com/specimen-requirements for details.

Specific site analysis for variants identified at an external laboratory must be accompanied by a copy of the original testing report. A positive control from a known positive family member is recommended (required for prenatal testing).

Reflex or Concurrent Testing

Concurrent testing is when multiple tests are initiated at the same time. When multiple tests are ordered on the same test requisition form, testing will be run concurrently unless otherwise specified.

Reflex testing is when a subsequent test is initiated pending the outcome of the initial test. Reflex testing may result in delayed reporting of results.

For reflex test orders:

- Any diagnostic finding at any step will result in cancellation of any subsequent reflex tests.
- Non-diagnostic findings (including VUS or Uncertain results) will automatically reflex to the subsequent test.
- Secondary findings results do not impact whether a subsequent test is initiated or canceled.

When ordering STAT panels (such as BRCAplus"), the results of the STAT panel will be prioritized and reported with a shorter turnaround time, even if the tests were run concurrently.

Known Familial Variants

Variant-specific report comments about the presence or absence of known familial variant(s) require the "Known Familial Variant" section of this form to be completed accurately, including an internal Ambry reference ID and/or a copy of the positive family member's lab report. Acceptable types of Ambry identifiers include:

- Accession number
- Order number
- · Name and date of birth

Variant requests without an internal Ambry reference ID or positive family member's lab report will not receive a variant-specific report comment.